background preloader

Drug_discovery

Facebook Twitter

Rational design of cancer-drug combinations. [N Engl J Med. 2007. Strategies for optimizing combinations o... [Nat Rev Drug Discov. 2006. Drugs for bad bugs: confronting the chal... [Nat Rev Drug Discov. 2007. Synthetic lethal screen identification of chemosensit... [Nature. 2007. Molecular Systems Biology. Robustness is one of the fundamental characteristics of biological systems.

Molecular Systems Biology

Numerous reports have been published on how robustness is involved in various biological processes and on mechanisms that give rise to robustness in living systems (Savageau, 1985a, 1985b, 1998; Barkai and Leibler, 1997; Alon et al, 1999; von Dassow et al, 2000; Bhalla and Iyengar, 2001; Csete and Doyle, 2002, 2004; Kitano et al, 2004, 2004a, 2004b; Stelling et al, 2004; Kitano and Oda, 2006; Kitano, 2007a). With increasing interest in systems biology, properties at the system level such as robustness have attracted serious scientific research. Nevertheless, a mathematical foundation that provides a unified perspective on robustness is yet to be established. Can the pharmaceutical industry reduce a... [Nat Rev Drug Discov. 2004. Thirty-three years of drug discovery and research with Dr. Paul Janssen - van Gestel - 2004 - Drug Development Research.

Contents: Nature Reprint Collection: Lilly: Drug Innovation. How to improve R&D productivity: the pharmaceutical industry's grand challenge : Article : Nature Reviews Drug Discovery. A proprotein convertase subtilisin/... [Proc Natl Acad Sci U S A. 2009. Chorus. The Chorus group got its start in 2002 as an alternative R&D pilot.

Chorus

The founders of Chorus believed they could transform the traditional drug development process through a lean approach to generating clinical proof of concept data with a more flexible virtual development model. The premise was simple: get as many early-stage compounds to proof-of-concept (PoC) and value step-up as quickly and cost effectively as possible. Here’s how it’s done and why we are different: Minimize parallel processing before there’s a validated mechanism and viable drug candidate.